|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1999-8-2
|
|
pubmed:abstractText |
(+/-)-3-[11C]Methyl-2-[4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-6 -methoxy-4(3H) quinazolinone ([+/-]-[11C]HX-CH 44) was labeled with carbon-11 using [11C]iodomethane with the corresponding N-demethylated precursor. Then, 30-90 mCi (1.10-3.33 GBq) of pure [11C]HX-CH 44 were obtained 30 min after end of bombardment with specific radioactivities of 500-1,400 mCi/micromol (18.5-51.8 GBq/micromol). Myocardial uptake in dogs was 0.340+/-0.043 pmol/mL tissue per nanomole injected, 10-15 min postinjection. Heart-to-lung ratio was 3 from the 5th to the 30th minute. Only 35% of the myocardial radioactivity could be displaced. Tissue uptake could not be blocked with appropriate compounds. Therefore, (+/-)-[11C]HX-CH 44 does not appear to be a suitable ligand for the study of myocardial beta1-adrenoceptors in positron emission tomography.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0969-8051
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
105-9
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10096509-Adrenergic beta-Antagonists,
pubmed-meshheading:10096509-Animals,
pubmed-meshheading:10096509-Carbon Radioisotopes,
pubmed-meshheading:10096509-Dogs,
pubmed-meshheading:10096509-Heart,
pubmed-meshheading:10096509-Ligands,
pubmed-meshheading:10096509-Lung,
pubmed-meshheading:10096509-Propanolamines,
pubmed-meshheading:10096509-Quinazolinones,
pubmed-meshheading:10096509-Radiopharmaceuticals,
pubmed-meshheading:10096509-Rats,
pubmed-meshheading:10096509-Rats, Sprague-Dawley,
pubmed-meshheading:10096509-Receptors, Adrenergic, beta-1,
pubmed-meshheading:10096509-Tomography, Emission-Computed
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Preliminary evaluation of 2-[4-[3-tert-butylamino)-2-hydroxypropoxy]phenyl]-3-methyl-6-me thoxy-4(3H)-quinazolinone ([+/-]HX-CH 44) as a selective beta1-adrenoceptor ligand for PET.
|
|
pubmed:affiliation |
Department de Recherche Medicale, Service Hospitalier Frederic Joliot, Orsay, France.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
